BiykemBozkurt (@biykemb) 's Twitter Profile
BiykemBozkurt

@biykemb

Editor-in-Chief JACC:HF, Senior Dean of Faculty, Prof of Med & Director of Center for Heart Failure, Mother of 3.
Views & opinions are my own

ID: 1025948047707127809

calendar_today05-08-2018 03:34:10

3,3K Tweet

5,5K Followers

1,1K Following

Mark Drazner (@markdrazner) 's Twitter Profile Photo

So honored to have my mentor, Dr. Lynne Stevenson, receive the 2021 HFSA Lifetime Achievement Award. She has trained a generation of advanced HF specialists, including me. I will always be indebted to her for leading me to this wonderful career path.🙏

So honored to have my mentor, Dr. Lynne Stevenson, receive the 2021 HFSA Lifetime Achievement Award. She has trained a generation of advanced HF specialists, including me. I will always be indebted to her for leading me to this wonderful career path.🙏
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

Simultaneous publications from #FINEARTSHF w #ACC2025 in JACC Journals & JAMA Cardiology 🔥 Reduction in New-Onset AF across CKM Spectrum 🔥 Effects on Mode of Death 🔥 Consistent Benefits across Functional Class, Kidney Risk & AF Subgroups Find out more 👇🏾 finearts-hf.org

Simultaneous publications from #FINEARTSHF w #ACC2025 in <a href="/JACCJournals/">JACC Journals</a> &amp; <a href="/JAMACardio/">JAMA Cardiology</a> 

🔥 Reduction in New-Onset AF across CKM Spectrum
🔥 Effects on Mode of Death
🔥 Consistent Benefits across Functional Class, Kidney Risk &amp; AF Subgroups

Find out more 👇🏾
finearts-hf.org
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

Wow! 😳 P3 #ZENITH RCT stopped early for overwhelming efficacy Sotatercept, an activin signaling inhibitor already proven to slow progression in lower risk PAH, now shown to dramatically ⬇️ death or worsening in advanced PAH HR 0.24 (0.13-0.43) P<0.001 nejm.org/doi/full/10.10…

Wow! 😳

P3 #ZENITH RCT stopped early for overwhelming efficacy

Sotatercept, an activin signaling inhibitor already proven to slow progression in lower risk PAH, now shown to dramatically ⬇️ death or worsening in advanced PAH

HR 0.24 (0.13-0.43) P&lt;0.001

nejm.org/doi/full/10.10…
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum jacc.org/doi/10.1016/j.…

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis

The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum

jacc.org/doi/10.1016/j.…
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies Partial de-escalation of GDMT might be safe in patients with low risk of relapse, although large trials are needed jacc.org/doi/10.1016/j.…

Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies

Partial de-escalation of GDMT might be safe in patients with low risk of relapse, although large trials are needed

jacc.org/doi/10.1016/j.…
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Finerenone Across the Spectrum of Kidney Risk in Heart Failure: FINEARTS-HF Trial Finerenone appears to consistently improve clinical outcomes, HF-related health status, and albuminuria across a broad spectrum of kidney risk in patients with HFmrEF/HFpEF jacc.org/doi/10.1016/j.…

Finerenone Across the Spectrum of Kidney Risk in Heart Failure: FINEARTS-HF Trial

Finerenone appears to consistently improve clinical outcomes, HF-related health status, and albuminuria across a broad spectrum of kidney risk in patients with HFmrEF/HFpEF

jacc.org/doi/10.1016/j.…
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Growth Hormone Replacement Therapy in HFREF : A Randomized, Double-Blind, Placebo-Controlled Trial GH replacement therapy in HFrEF patients with GHD improves exercise performance, and left ventricular and right ventricular structure and function jacc.org/doi/10.1016/j.…

Growth Hormone Replacement Therapy in HFREF : A Randomized, Double-Blind, Placebo-Controlled Trial

GH replacement therapy in HFrEF patients with GHD improves exercise performance, and left ventricular and right ventricular structure and function

jacc.org/doi/10.1016/j.…
HFAPresident (@hfa_president) 's Twitter Profile Photo

HFA Eugene Braunwald Lecture by Dr. Lynne Stevenson — celebrating her groundbreaking contributions and lasting impact on the world of heart failure. A true pioneer! #HeartFailure2025 Novi Yanti Sari Wilfried Mullens Amr Abdin European Society of Cardiology

HFA Eugene Braunwald Lecture by Dr. Lynne Stevenson — celebrating her groundbreaking contributions and lasting impact on the world of heart failure. A true pioneer! #HeartFailure2025 
<a href="/slumberbell/">Novi Yanti Sari</a> <a href="/WilfriedMullens/">Wilfried Mullens</a> <a href="/AmrAbdin10/">Amr Abdin</a> <a href="/escardio/">European Society of Cardiology</a>
Nikolay Novitskiy (@novitskiynic) 's Twitter Profile Photo

HFA Eugene Braunwald Lecture by Wilfried Mullens - Lynne Warner Stevenson and her incredible contribution to HF Lead investigator 500+ publications Editorial board member 7 journals Contributor to 30+ HF guidelines Trained 70 HF fellows (50% women) #HeartFailure2025

HFA Eugene Braunwald Lecture by <a href="/WilfriedMullens/">Wilfried Mullens</a> - 
Lynne Warner Stevenson and her incredible contribution to HF

Lead investigator
500+ publications
Editorial board member 7 journals
Contributor to 30+ HF guidelines
Trained 70 HF fellows (50% women) 

#HeartFailure2025
Nikhil Narang, MD (@nikhil15) 's Twitter Profile Photo

New brief report in JACC Journals #JACCHF evaluating feasibility of withdrawing #GDMT and keeping pts w/ HFimpEF (EF <40 hx➡️ >50) just on carvedilol (50 mg/day) ✅ no sig difference in HF/EF at 52 weeks Opposing trial results vs. TRED-HF? 📎 jacc.org/doi/10.1016/j.…

New brief report in <a href="/JACCJournals/">JACC Journals</a> #JACCHF evaluating feasibility of withdrawing #GDMT and keeping pts w/ HFimpEF (EF &lt;40 hx➡️ &gt;50) just on carvedilol (50 mg/day)

✅ no sig difference in HF/EF at 52 weeks 

Opposing trial results vs. TRED-HF? 

📎 jacc.org/doi/10.1016/j.…
HF Collaboratory (@hfcollaboratory) 's Twitter Profile Photo

At the #3CT #HFC members are leading the way in the session "Acute #HeartFailure: Ready for Personalized Post-Discharge?" Christopher O'Connor (moderator) BiykemBozkurt on devices & GDM Randi Rising on QOL > survival Plus Mitchell Psotka Maria Rosa Costanzo @FudimMara also presenting across key sessions

At the #3CT #HFC members are leading the way in the session "Acute #HeartFailure: Ready for Personalized Post-Discharge?"
<a href="/coconnormd/">Christopher O'Connor</a> (moderator) <a href="/BiykemB/">BiykemBozkurt</a> on devices &amp; GDM <a href="/RandiRising/">Randi Rising</a> on QOL &gt; survival
Plus <a href="/mpsotka/">Mitchell Psotka</a> <a href="/mrchrtfaildoc/">Maria Rosa Costanzo</a> @FudimMara also presenting across key sessions